EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Nuclear Imaging and Echocardiographic Findings in Hypertrophic Cardiomyopathy with and without ATTR-CM

Pablo Garcia-Pavia iD, Francisco Javier Haro Del Moral, Francesco Cappelli iD, Nicolas Piriou, Roberto Barriales-Villa, Carmen Munteanu, Catherine Bahus, Denis Keohane, Pablo Mallaina, Emmanuel Itti, Thibaud Damy, Perry Elliott

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15440 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Pablo Garcia-Pavia und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, Majadahonda, Spain. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Tomography, Emission-Computed, Single-Photon, Echocardiography, Amyloid Neuropathies, Familial. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) often experience delayed diagnosis, which may detrimentally impact clinical outcomes. This study aimed to assess the frequency of use of planar scintigraphy with and without single-photon emission computed tomography (SPECT) in patients with hypertrophic cardiomyopathy (HCM) screened for ATTR-CM in the TTRACK study. Variability in readings based on different readers, tests and radiotracers used in cardiac nuclear imaging, and differences in echocardiogram findings between patients with and without ATTR-CM were explored.

Methods

Patients aged ≥50 years with HCM (left-ventricular wall thickness ≥15 mm without an identified cause) underwent diagnostic technetium-99m [99mTc]Tc-DPD [3,3-diphosphono-1,2-propanodicarboxylic acid], -PYP [pyrophosphate] and -HMDP [hydroxymethylene diphosphonate]–labelled planar bone scintigraphy with or without SPECT. Cardiac-versus-bone uptake on images was visually graded (Perugini, 0–3) by onsite and central readers (discrepancies resolved by consensus). Patients with grade 1–3 cardiac uptake underwent monoclonal protein testing.

Results

Of 766 eligible patients (mean age ± standard deviation, 72.3 ± 10.6 years, 69.6% male), 691 (90.2%) had planar imaging alone and 75 (9.8%) planar plus SPECT imaging. Cardiac uptake was observed on imaging in 245 patients (32.0%); grades 1, 2 and 3 were assigned in 37 (4.8%), 34 (4.4%) and 174 (22.7%), respectively. Initial cardiac uptake grading for planar scintigraphy by onsite readers was strongly concordant with consensus decisions [κ coefficient, 0.84 (95% confidence interval 0.81–0.88)]. Grading for planar versus SPECT imaging was very strongly concordant [0.93 (95% confidence interval 0.86–1.00)]; discordant findings were only observed with [99mTc]Tc-PYP. Compared with patients with no cardiac uptake, patients with ATTR-CM had a lower mean left ventricular (LV) ejection fraction (55.7% vs. 61.4%; P < 0.001), higher mean LV mass index (179.0 vs. 155.6 g/m2; P < 0.01), a higher rate of preserved apical strain (73.4% vs. 57.9%; P < 0.05) and differences in hypertrophic pattern (P < 0.001), such as a higher rate of concentric hypertrophic pattern (77.5% vs. 38.8%;). Clinical overlap between patients with ATTR-CM and those without cardiac uptake was high.

Conclusions

In this real-world study, a high level of concordance was seen in cardiac uptake grading on planar versus SPECT imaging, with discordant findings only observed with [99mTc]Tc-PYP. The findings support the use of these imaging tools to facilitate ATTR-CM screening in clinical practice. Further studies should investigate differences across tracers used in ATTR-CM screening. NCT03842163.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicTomography, Emission-Computed, Single-PhotonEchocardiographyAmyloid Neuropathies, FamilialHeart VentriclesHumansMaleFemaleMiddle AgedAgedRadiopharmaceuticals

Stichwörter der Autor:innen

SPECTechocardiogramhypertrophic cardiomyopathyscintigraphytransthyretin amyloid cardiomyopathy

Substanzen

Radiopharmaceuticals

Autor:innen und Institutionen

  • Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, Majadahonda, Spain.
  • Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
  • Universidad Francisco de Vitoria (UFV), Pozuelo de Alarcon, Spain.
  • Careggi University Hospital, Florence, Italy.
  • L'institut du Thorax and Nuclear Medicine Department, CHU Nantes, Nantes Université, Nantes, France.
  • Complexo Hospitalario Universitario A Coruña, INIBIC, CIBERCV, A Coruña, Spain.

ORCID-Profile: Pablo Garcia-Pavia, Francesco Cappelli

Förderung

  • Pfizer

Zitieren

APA

Garcia-Pavia, P., Del Moral, F. J. H., Cappelli, F., Piriou, N., Barriales-Villa, R., Munteanu, C., Bahus, C., Keohane, D., Mallaina, P., Itti, E., Damy, T., & Elliott, P. (2025). Nuclear Imaging and Echocardiographic Findings in Hypertrophic Cardiomyopathy with and without ATTR-CM. ESC Heart Failure. https://doi.org/10.1002/ehf2.15440

Vancouver

Garcia-Pavia P, Del Moral FJH, Cappelli F, Piriou N, Barriales-Villa R, Munteanu C, et al. Nuclear Imaging and Echocardiographic Findings in Hypertrophic Cardiomyopathy with and without ATTR-CM. ESC Heart Failure. 2025. doi:10.1002/ehf2.15440

BibTeX
@article{GarciaPavia2025,
  author = {Garcia-Pavia, Pablo and Del Moral, Francisco Javier Haro and Cappelli, Francesco and Piriou, Nicolas and Barriales-Villa, Roberto and Munteanu, Carmen and Bahus, Catherine and Keohane, Denis and Mallaina, Pablo and Itti, Emmanuel and Damy, Thibaud and Elliott, Perry},
  title = {Nuclear Imaging and Echocardiographic Findings in Hypertrophic Cardiomyopathy with and without ATTR-CM},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15440}
}
Kostenlos starten →